Dianthus Therapeutics, Inc. /DE/ shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-21 meeting.
“For Against Abstain Broker Non-Votes 46,298,319 5,279 500,471 —”
Dianthus Therapeutics, Inc. /DE/ — fact timeline
Source-grounded facts extracted from Dianthus Therapeutics, Inc. /DE/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dianthus Therapeutics, Inc. /DE/ shareholders approved Election of Class II Directors at the 2026-05-21 meeting.
“Nominees For Withheld Broker Non-Votes Sujay Kango 42,739,315 479,199 3,585,554 Anne McGeorge 34,814,377 8,404,137 3,585,554 Jonathan Violin, Ph.D 42,799,946 418,568 3,585,554”
Dianthus Therapeutics, Inc. /DE/ reported financial results for the first quarter ending March 31, 2026.
“On May 5, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.”
Dianthus Therapeutics, Inc. /DE/ entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters valued at approximately $673.5 million (effective 2026-03-10).
“On March 10, 2026, Dianthus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 7,313,582 shares of the Company’s common stock at a public offering price of $81.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 402,468 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a public offering price of $80.999 per share, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each Pre-Funded Warrant (the “Offering”).”
Dianthus Therapeutics, Inc. /DE/ reported the fourth quarter and full year ending December 31, 2025 results: net income $162.3 million or $4.20 per share, EPS $4.20 per share.
“On March 9, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and full year ended December 31, 2025.”
Simon Read was appointed as Class III director at Dianthus Therapeutics, Inc. /DE/.
“On May 22, 2025, the Board appointed Simon Read, Ph.D., as a Class III director of the Company and as a member of both the Science and Technology Committee of the Board (the “S&T” Committee) and the Nominating and Corporate Governance Committee of the Board (the “N&CG” Committee), effective immediately.”
Leon O. Moulder, Jr. resigned as Director at Dianthus Therapeutics, Inc. /DE/.
“On May 22 2025, Leon O. Moulder, Jr., a member of the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately.”
Sujay Kango was appointed as Director at Dianthus Therapeutics, Inc. /DE/.
“On March 4, 2025, the Board appointed Sujay Kango as a Class II director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”), effective immediately after close of business on March 4, 2025.”
Tomas Kiselak resigned as Director at Dianthus Therapeutics, Inc. /DE/.
“On March 4, 2025, Tomas Kiselak, a member of the Board of Directors (the “Board) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective as of the close of business on March 4, 2025.”
Steven Romano, M.D. was appointed as Class III director at Dianthus Therapeutics, Inc. /DE/.
“On September 16, 2024, the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”) appointed Steven Romano, M.D. as a Class III director of the Company and as a member of the Science and Technology Committee of the Board (the “S&T Committee”), effective immediately.”
Dianthus Therapeutics, Inc. /DE/ reported the quarter ended March 31, 2024 results: net income $13.7 million, EPS $0.54 net loss per share (basic and diluted).
“Net loss for the quarter ended March 31, 2024 was $13.7 million or $0.54 net loss per share (basic and diluted)”
Dianthus Therapeutics, Inc. /DE/ reported the year ended December 31, 2023 results: net income $43.6 million, EPS $8.45 net loss per share (basic and diluted).
“Net loss for the year ended December 31, 2023 was $43.6 million or $8.45 net loss per share (basic and diluted)”
Dianthus Therapeutics, Inc. /DE/ entered into Registration Rights Agreement with Institutional and accredited investors valued at Registration Rights Agreement for resale registration (effective 2024-01-22).
“Also on January 22, 2024, the Company entered into a Registration Rights Agreement (the "Registration Rights Agreement") with the Purchasers, which provides that the Company will register the resale of the Common Shares and the Pre-Funded Warrant Shares.”
Dianthus Therapeutics, Inc. /DE/ entered into Securities Purchase Agreement with Institutional and accredited investors valued at 230,000,000 USD (effective 2024-01-22).
“On January 22, 2024, Dianthus Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a Securities Purchase Agreement (the "Purchase Agreement") for a private placement (the "Private Placement") with certain institutional and accredited investors (each, a "Purchaser" and collectively, the "Purchasers").”
Dianthus Therapeutics, Inc. /DE/ reported third quarter ending September 30, 2023 results: net income $14.8 million, EPS $3.78 net loss per share (basic and diluted).
“Net loss for the quarter ended September 30, 2023 was $14.8 million or $3.78 net loss per share (basic and diluted).”
Dianthus Therapeutics, Inc. /DE/ engaged Deloitte & Touche LLP as its auditor.
“on September 11, 2023, following the completion of the merger between the subsidiary of Dianthus Therapeutics, Inc. (the "Company," formerly known as Magenta Therapeutics, Inc.) and Dianthus Therapeutics OpCo, Inc. (formerly known as Dianthus Therapeutics, Inc.), the Audit Committee of the Company approved the appointment of Deloitte & Touche LLP (“Deloitte”) as the independent registered public accounting firm of the Company. The Company’s engagement of Deloitte was subject to completion of Deloitte’s standard client acceptance procedures and execution of an engagement letter, which was fully executed by the Company on October 19, 2023”
Lei Meng was appointed as Class III Director at Dianthus Therapeutics, Inc. /DE/.
“As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.”
Leon O. Moulder, Jr. was appointed as Class III Director at Dianthus Therapeutics, Inc. /DE/.
“As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.”
Jonathan Violin, Ph.D. was appointed as Class II Director at Dianthus Therapeutics, Inc. /DE/.
“As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.”
Tomas Kiselak was appointed as Class II Director at Dianthus Therapeutics, Inc. /DE/.
“As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.”
Paula Soteropoulos was appointed as Class I Director at Dianthus Therapeutics, Inc. /DE/.
“As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.”
Marino Garcia was appointed as Class I Director at Dianthus Therapeutics, Inc. /DE/.
“As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.”
Dianthus Therapeutics, Inc. /DE/: Adoption of a new Code of Conduct and Ethics, superseding the prior code.
“the Board of Directors adopted a new Code of Conduct and Ethics (the “ Code of Conduct ”). The Code of Conduct superseded the Company’s existing code of business conduct and ethics previously adopted by the Board of Directors”
Dianthus Therapeutics, Inc. /DE/: Amendment to restated certificate of incorporation to effect a 1-for-16 reverse stock split (effective 2023-09-11).
“the Company filed a Fifth Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “ A&R Charter ”), with an effective time of 11:13 a.m. Eastern Time on September 11, 2023”
Dianthus Therapeutics, Inc. /DE/ underwent a change of control involving Dianthus Therapeutics OpCo, Inc. for approximately 11,021,300 shares of Common Stock (closed 2023-09-11).
“Merger, each share of OpCo preferred stock was converted into a share of OpCo common stock. At the effective time of the Merger, the Company issued an aggregate of approximately 11,021,300 shares of Common Stock to OpCo stockholders, based on an exchange ratio of approximately 0.2181 shares of Common Stock for each share of OpCo capital stock, including those shares”
Dianthus Therapeutics, Inc. /DE/ engaged Deloitte & Touche LLP as its auditor.
“On September 11, 2023, following the completion of the Merger, the Audit Committee approved the appointment of Deloitte as the independent registered public accounting firm of the Company.”
Dianthus Therapeutics, Inc. /DE/ dismissed KPMG LLP as its auditor.
“On September 11, 2023, following the completion of the Merger, KPMG was dismissed as the independent registered public accounting firm of the Company.”
Jonathan Violin was appointed as Director at Dianthus Therapeutics, Inc. /DE/.
“six members designated by OpCo, who are Marino Garcia, Leon O. Moulder, Jr., Tomas Kiselak, Lei Meng, Paula Soteropoulos and Jonathan Violin, Ph.D.”
Paula Soteropoulos was appointed as Director at Dianthus Therapeutics, Inc. /DE/.
“six members designated by OpCo, who are Marino Garcia, Leon O. Moulder, Jr., Tomas Kiselak, Lei Meng, Paula Soteropoulos and Jonathan Violin, Ph.D.”
Lei Meng was appointed as Director at Dianthus Therapeutics, Inc. /DE/.
“six members designated by OpCo, who are Marino Garcia, Leon O. Moulder, Jr., Tomas Kiselak, Lei Meng, Paula Soteropoulos and Jonathan Violin, Ph.D.”
Tomas Kiselak was appointed as Director at Dianthus Therapeutics, Inc. /DE/.
“six members designated by OpCo, who are Marino Garcia, Leon O. Moulder, Jr., Tomas Kiselak, Lei Meng, Paula Soteropoulos and Jonathan Violin, Ph.D.”
Leon O. Moulder, Jr. was appointed as Chair of the Board of Directors at Dianthus Therapeutics, Inc. /DE/.
“Chair of the Board of the Directors Mr. Moulder was appointed as the chair of the Board of Directors.”
Leon O. Moulder, Jr. was appointed as Director at Dianthus Therapeutics, Inc. /DE/.
“six members designated by OpCo, who are Marino Garcia, Leon O. Moulder, Jr., Tomas Kiselak, Lei Meng, Paula Soteropoulos and Jonathan Violin, Ph.D.”
Marino Garcia was appointed as Director at Dianthus Therapeutics, Inc. /DE/.
“six members designated by OpCo, who are Marino Garcia, Leon O. Moulder, Jr., Tomas Kiselak, Lei Meng, Paula Soteropoulos and Jonathan Violin, Ph.D.”
Stephen Mahoney departed as President, Chief Financial and Operating Officer at Dianthus Therapeutics, Inc. /DE/.
“Immediately after closing of the Merger, Stephen Mahoney, President, Chief Financial and Operating Officer, was terminated without cause as part of the transaction and is pursuing other opportunities.”
Michael Vasconcelles resigned as Director at Dianthus Therapeutics, Inc. /DE/.
“Jeffrey W. Albers, Bruce Booth, D. Phil., Thomas O. Daniel, M.D., Amy Lynn Ronneberg, David T. Scadden, M.D. and Michael Vasconcelles, M.D. resigned from the Board of Directors and committees of the Board of Directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
David T. Scadden resigned as Director at Dianthus Therapeutics, Inc. /DE/.
“Jeffrey W. Albers, Bruce Booth, D. Phil., Thomas O. Daniel, M.D., Amy Lynn Ronneberg, David T. Scadden, M.D. and Michael Vasconcelles, M.D. resigned from the Board of Directors and committees of the Board of Directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Amy Lynn Ronneberg resigned as Director at Dianthus Therapeutics, Inc. /DE/.
“Jeffrey W. Albers, Bruce Booth, D. Phil., Thomas O. Daniel, M.D., Amy Lynn Ronneberg, David T. Scadden, M.D. and Michael Vasconcelles, M.D. resigned from the Board of Directors and committees of the Board of Directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Thomas O. Daniel resigned as Director at Dianthus Therapeutics, Inc. /DE/.
“Jeffrey W. Albers, Bruce Booth, D. Phil., Thomas O. Daniel, M.D., Amy Lynn Ronneberg, David T. Scadden, M.D. and Michael Vasconcelles, M.D. resigned from the Board of Directors and committees of the Board of Directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Bruce Booth resigned as Director at Dianthus Therapeutics, Inc. /DE/.
“Jeffrey W. Albers, Bruce Booth, D. Phil., Thomas O. Daniel, M.D., Amy Lynn Ronneberg, David T. Scadden, M.D. and Michael Vasconcelles, M.D. resigned from the Board of Directors and committees of the Board of Directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Jeffrey W. Albers resigned as Director at Dianthus Therapeutics, Inc. /DE/.
“Jeffrey W. Albers, Bruce Booth, D. Phil., Thomas O. Daniel, M.D., Amy Lynn Ronneberg, David T. Scadden, M.D. and Michael Vasconcelles, M.D. resigned from the Board of Directors and committees of the Board of Directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
Dianthus Therapeutics, Inc. /DE/ shareholders approved Ratify selection of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-09-08 meeting.
“Proposal No. 5 – To ratify the selection of KPMG LLP as Magenta’s independent registered public accounting firm for the fiscal year ending December 31, 2023, provided that Deloitte & Touche LLP is expected to be appointed for that fiscal year if the merger is completed. This proposal was approved by the requisite vote of the Company’s stockholders.”
Dianthus Therapeutics, Inc. /DE/ shareholders approved Election of three Class II director nominees at the 2023-09-08 meeting.
“Proposal No. 4 – To elect three Class II director nominees named in the accompanying proxy statement/prospectus to Magenta’s board of directors, to serve until Magenta’s 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. The Company’s stockholders elected Mr. Albers, Ms. McGeorge and Dr. Scadden.”
Dianthus Therapeutics, Inc. /DE/ shareholders rejected Approve amendment to charter to provide for exculpation of officers at the 2023-09-08 meeting.
“Proposal No. 3 – To approve an amendment to Magenta’s charter to provide for the exculpation of officers. This proposal was not approved by the requisite vote of the Company’s stockholders.”
Dianthus Therapeutics, Inc. /DE/ shareholders approved Approve amendment to charter to effect a reverse stock split in the range 1:10 to 1:18 at the 2023-09-08 meeting.
“Proposal No. 2 – To approve an amendment to the amended and restated certificate of incorporation of Magenta (“Magenta’s charter”) to effect a reverse stock split of Magenta’s issued and outstanding common stock at a ratio in the range between 1:10 to 1:18, inclusive, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by the Magenta board of directors and the Dianthus board of directors prior to the effective time or, if the Proposal No. 1 is not approved by Magenta stockholders, determined solely by the Magenta board of directors. This proposal was approved by the requisite vote of the Company’s stockholders.”
Dianthus Therapeutics, Inc. /DE/ shareholders approved Approve issuance of shares and change of control in connection with merger at the 2023-09-08 meeting.
“Proposal No. 1 – To approve (i) the issuance of shares of common stock of Magenta, which will represent more than 20% of the shares of Magenta common stock outstanding immediately prior to the merger, to stockholders of Dianthus, pursuant to the terms of the Merger Agreement, a copy of which is attached as Annex A to the accompanying proxy statement/prospectus, and (ii) the change of control of Magenta resulting from the merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively. This proposal was approved by the requisite vote of the Company’s stockholders.”
Dr. Lisa Olson departed as Head of Research and Chief Scientific Officer at Dianthus Therapeutics, Inc. /DE/.
“Effective May 15, 2023, Dr. Lisa Olson, Head of Research and Chief Scientific Officer of Magenta Therapeutics, Inc. (the “Company” or “Magenta”), has left the Company due to the completion of the sale of certain of Magenta’s assets and its announced proposed merger with Dianthus Therapeutics, Inc. (“Dianthus”).”
Dianthus Therapeutics, Inc. /DE/ entered into Agreement and Plan of Merger with Magenta Therapeutics, Inc. (effective 2023-05-02).
“On May 2, 2023, Magenta Therapeutics, Inc., a Delaware corporation (“Magenta”), Dio Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Magenta (“Merger Sub”), and Dianthus Therapeutics, Inc., a Delaware corporation (“Dianthus”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)”
Dianthus Therapeutics, Inc. /DE/: The Board approved a Certificate of Designations to create a new series of preferred stock, Series A Junior Participating Cumulative Preferred Stock, in connection with the adoption of a Rights Agreement (effective 2023-03-31).
“In connection with the adoption of the Rights Agreement described in Item 1.01 above, the Board of Directors of the Company approved a Certificate of Designations of Series A Junior Participating Cumulative Preferred Stock (the “Certificate of Designations”). The Certificate of Designations will be filed with the Secretary of State of Delaware on March 31, 2023.”
Dianthus Therapeutics, Inc. /DE/ announced a restructuring with charges of $5.4 million (up to 56 positions, or approximately 84%).
“or approximately 84%, to be substantially completed by February 17, 2023. As a result of the Plan, the Company expects to incur estimated severance and related costs of $5.4 million by the end of February 2023. Each departing employee of Magenta has played an integral role in the Company’s mission of improving stem cell transplant to enable access for more”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.